Drug Topics
APRIL 23, 2024
Abeona Therapeutics’ pz-cel is an investigational autologous, COL7A1 gene-corrected epidermal sheet therapy for the treatment of recessive dystrophic epidermolysis bullosa.
Pharmacy Times
APRIL 23, 2024
The approval was based on the QUILT-3.032 study, which included 77 adults with carcinoma in situ with or without papillary tumors after a transurethral resection.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
APRIL 23, 2024
Collecting smell and taste scores from individuals with and without a history of COVID-19, researchers found significantly lower scores for smell in COVID-19-diagnosed individuals.
STAT
APRIL 23, 2024
WASHINGTON — Testing conducted by the Food and Drug Administration on pasteurized commercially purchased milk has found genetic evidence of the H5N1 bird flu virus, the agency confirmed Tuesday. But the testing, done by polymerase chain reaction, or PCR, cannot distinguish between live virus or fragments of viruses that could have been killed by the pasteurization process.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharmacy Times
APRIL 23, 2024
The AAN speaker highlights what health care providers need to know when treating migraines in populations on hormone therapy, as well as how hormones can influence migraines.
STAT
APRIL 23, 2024
Anyone who has gone to a hospital’s emergency room expecting to receive medical care — not knowing where else to turn, uncertain whether a loved one is having a medical emergency and what can be done about it, or unsure if they can pay — has relied on a law they couldn’t name: the Emergency Medical Treatment and Labor Act (EMTALA).
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
STAT
APRIL 23, 2024
The Federal Trade Commission approved a far-reaching noncompete ban Tuesday that could force sweeping changes across the health care industry. But those changes may not take effect for years — if they ever do — because the contentious rule will almost certainly be held up in litigation. Commissioners voted three to two in favor of approving the final rule banning noncompete agreements across all sectors of the economy, a change the agency says will lead to more new businesses and h
Pharmacy Times
APRIL 23, 2024
This approval makes lutetium Lu177 the first therapy to be approved for the treatment of gastroenteropancreatic neuroendocrine tumors in pediatric patients.
Fierce Healthcare
APRIL 23, 2024
The Federal Trade Commission (FTC) voted 3-2 Tuesday to issue a final rule striking new noncompete agreements for all workers and phasing out existing noncompetes for all but senior executives acro | The final rule, which does not apply to nonprofits, forbids noncompete contracts for all new hires and winds down existing noncompetes for all employees who are not senior executives.
Fierce Pharma
APRIL 23, 2024
Giovanni Caforio, M.D., is lining up a new gig soon after handing all his Bristol Myers Squibb leadership roles in March. | Giovanni Caforio, M.D., is lining up a new gig soon after handing all his Bristol Myers Squibb leadership roles in March. The recent Big Pharma CEO, known for steering the $74 billion acquisition of Celgene, has been proposed as the new chair at Novartis for 2025.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
STAT
APRIL 23, 2024
D ay One Biopharmaceuticals said Tuesday the Food and Drug Administration approved its pill for one of the most common forms of childhood brain tumors, called pediatric low-grade glioma. The authorization is particularly notable because industry has historically developed few drugs for children with cancer, focusing instead on adults and often only years later testing their molecules in younger patients.
Drug Topics
APRIL 23, 2024
The approval for tovorafenib (Ojemda) was based on data from the phase 2 FIREFLY-1 trial, in which the therapy demonstrated an overall repose rate of 67%.
STAT
APRIL 23, 2024
The trend is clear: When hospitals in the same community merge, prices spike. The government has such an easy time blocking those deals, hospitals rarely propose them anymore. But a study released Tuesday adds to a growing body of evidence that prices still go up even if the merging hospitals are far apart. The Federal Trade Commission has never tried to block such cross-market mergers, but antitrust experts say these latest findings add to what could become a strong legal argument against the d
Pharmacy Times
APRIL 23, 2024
Laura Gillespie, PharmD, discusses the impact of pharmacist-led initiatives on health care–associated C diff rates for health care systems.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
STAT
APRIL 23, 2024
If her neurologist moved to China, Lauren Stiles says she’d follow him there. “There’s so few doctors who do this,” said the New York-based president of patient advocacy group Dysautonomia International. In her world, informed, experienced specialists — particularly in the autonomic nervous system — are extremely rare.
Fierce Healthcare
APRIL 23, 2024
More than 1,600 Blue Shield of California members have registered for a musculoskeletal (MSK) program through the payer's digital health platform since its launch in January. | Less than 2,000 members have registered for musculoskeletal health programs through the Blue Shield of California digital platform, but the insurer hopes to see growth ramp up soon.
STAT
APRIL 23, 2024
My chief resident gave me a strange look when I arrived for another day of work at the Mayo Clinic one morning. “Something you’re not telling us?” she asked, gesturing to the two letters on my desk from the Central Intelligence Agency. The jokes — about how I was secretly working for America’s international spy service — wrote themselves.
Fierce Healthcare
APRIL 23, 2024
Medicaid managed care plans and the Children’s Health Insurance Program (CHIP) will be subject to new wait time standards and quality ratings requirements, the Centers for Medicare & Medicaid S | CMS defended implementing stronger rules over nursing home staffing as well as explained its thoughts behind Medicaid access and managed care rules.
STAT
APRIL 23, 2024
The National Institutes of Health will raise the minimum salary for postdoctoral researchers to $61,008 next year, the agency announced Tuesday, responding to growing calls from young life scientists to provide a living wage. The 8% pay bump is far short of the increase to $70,000 that was recommended by an NIH working group late last year. But the agency noted in a press release that it’s the largest year-over-year update for NIH-funded postdocs since 2017.
pharmaphorum
APRIL 23, 2024
After rejecting ImmunityBio’s Anktiva last year, the FDA has now cleared the drug as a treatment for bladder cancer, making it the biotech's first commercial-stage product
Fierce Healthcare
APRIL 23, 2024
Alaffia Health, a health tech business that works with payers and third-party administrators to minimize fraud and help clinicians conduct reviews more efficiently, has raised $10 million in series | Alaffia Health's revenue has increased 4x in the last year. Here's how its AI tools help payer partners save money and be more efficient.
STAT
APRIL 23, 2024
WASHINGTON — Congress did nothing this spring to rein in how pharmacy benefit managers operate, which is precisely the outcome the industry’s lobbyists wanted. And the PBM industry spent big to get that result, new disclosures show. The Pharmaceutical Care Management Association, the industry’s biggest trade group, spent a whopping 71% more on lobbying in the first three months of this year compared with 2023, increasing its spending from $2.8 million to $4.8 million.
Fierce Healthcare
APRIL 23, 2024
The Supreme Court will hear oral arguments tomorrow morning in a case highlighting the clash between federal emergency care requirements and state laws banning abortion services. | The top court will hear from the Department of Justice and the state of Idaho on how EMTALA requirements may or may not conflict with state abortion bans, and whether the federal emergency care law was meant to apply to abortion care.
STAT
APRIL 23, 2024
In the early days of the pandemic, as social distancing forced patients out of doctors’ offices, health care organizations scrambled to offer care online. In turn, health care accreditation organizations rushed to tweak their standards, filling a void in best practices for virtual visits. But as telehealth has matured, accreditation bodies — typically nonprofits that offer a seal of approval to organizations that pass their audits — are trying to address the nuance of digita
Fierce Pharma
APRIL 23, 2024
The orphan drug sector has long been clearing growth in the larger pharmaceutical market with booming sales. | The orphan drug sector has long been clearing growth in the larger pharmaceutical market with booming sales. But thanks to blockbuster meds across wider disease areas and other challenges, the lucrative market may soon slow down for the first time in years.
Drug Topics
APRIL 23, 2024
The action taken by CVS staffers seems to be the only way to get the attention of corporate officials.
Fierce Pharma
APRIL 23, 2024
As doctors and patients in the U.S. | As doctors and patients in the U.S. grapple with widening shortages of the popular diabetes therapy Mounjaro and its obesity counterpart Zepbound, the maker of the tirzepatide drugs, Eli Lilly, is forging ahead on its quest to expand capacity for its injectable medicines.
pharmaphorum
APRIL 23, 2024
Unlock the power of digital health through AI and clinical advancements. Learn how these technologies are shaping the future of healthcare and how to harness their potential.
Pharmaceutical Commerce
APRIL 23, 2024
In an interview with Pharma Commerce Associate Editor Nicholas Saraceno, Will Robinson, Commercial Director, LogiPharma, talks themes of this year's event and future plans for the show.
Pharmaceutical Technology
APRIL 23, 2024
The European Commission (EC) has granted marketing authorisation for Pfizer’s EMBLAVEO (aztreonam-avibactam), aimed at treating adults with multidrug-resistant infections where treatment options are limited.
Outsourcing Pharma
APRIL 23, 2024
At CPhI North America, Quotient Sciences is looking forward to reconnecting with its customers and giving them a preview of how we are looking to expand Translational Pharmaceutics further within the US.
PioneerRx
APRIL 23, 2024
The summer is rapidly approaching. From getting ready for graduation ceremonies to preparing for your favorite user conference (hello, Catalyst Connect 2024).
Outsourcing Pharma
APRIL 23, 2024
In a major partnership aimed at accelerating research into Rett syndrome, a rare neurological disorder predominantly affecting girls, digital healthcare solutions company Vivalink, has joined forces with the Rett Syndrome Research Trust (RSRT).
Fierce Pharma
APRIL 23, 2024
Another drug is in town for common pediatric brain tumors. Compared with an incumbent offering from Novartis, the newcomer boasts an FDA approval covering a broader patient population. | Another drug is in town for common pediatric brain tumors. Compared with an incumbent offering from Novartis, Day One's newcomer boasts an FDA approval covering a broader patient population.
Expert insights. Personalized for you.
208 
Let's personalize your content